(4 years, 6 months ago)
Lords ChamberMy Lords, I declare my interests as chief executive of Breast Cancer Now, the research and care charity, and as chair of the National Cancer Research Institute. In these uncertain times, medical research charities have been deeply committed to the national effort against Covid-19 as funders and patient support organisations. Action has been taken across the sector to deliver additional support services and, of course, to second clinical researchers to the front line of the NHS. The contribution of medical research charities is at risk now and for the future if charities do not have the vital funding at this time of heightened demand.
The impact of Covid-19 has been far greater than many charities could have foreseen and the consequences are far-reaching, as we know. Many medical research charities are reliant on fundraising, which is extremely challenging now. Many have had to protect their income and reserves by furloughing a significant proportion of staff, including research staff. Yet, worryingly, medical research charities really do look unlikely to be able to benefit from the support packages announced by the Chancellor recently. In 2019, these charities collectively invested, as we heard, £1.9 billion in the UK R&D set-up. Uncertainty around fundraising in a challenging economic climate poses a real threat to sustainable funding in medical research, since charitable investment is, as we know, critical to the success of the UK’s life sciences sector.
Will the Minister consider new ways that the Government can work in partnership with medical research charities to mitigate the impact of Covid-19 on the research sector? Solutions will need to be tailored and focused on ensuring continuity of charity-funded research now, but also for the future—for cancer research, heart disease, long-term conditions and mental health. We need to kick-start the UK’s research ecosystem when we get through this. This will be of huge benefit to the economy. Of course, it is all about saving lives too.